Post on 27-Jun-2022
Q1
Q11
Q2
Clinical Gastroenterology and Hepatology 2020;-:-–-
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
Maintenance of Remission With Tofacitinib Therapy inPatients With Ulcerative Colitis
Jean-Frederic Colombel,* Mark T. Osterman,‡ Andrew J. Thorpe,§
Leonardo Salese,§ Chudy I. Nduaka,§ Haiying Zhang,§ Nervin Lawendy,§
Gary S. Friedman,§ Daniel Quirk,§ Chinyu Su,§ and Walter Reinischjj
7071
72
*Icahn School of Medicine at Mount Sinai, New York, New York; ‡University of Pennsylvania, Perelman School of Medicine,Philadelphia, Pennsylvania; §Pfizer, Collegeville, Pennsylvania; and ||Medical University of Vienna, Vienna, Austria73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
BACKGROUND & AIMS:Abbreviations used in this papeconfidence interval; FAS, full anrate; LOCF, last observation cadiovascular events; NMSC, nonimputation; OLE, open-label,score; TNFi, tumor necrosis fac
F
92
93
94
95
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerativecolitis (UC). The efficacy and safety of tofacitinib in patients with moderate to severe UC, up to 1year, have been reported. We investigated maintenance of efficacy in patients in remission after52 weeks of maintenance treatment in the pivotal phase 3 study (OCTAVE Sustain); these pa-tients received open-label, long-term treatment with tofacitinib 5 mg twice daily.
96
97
METHODS: 9899
100
101
102
103
Patients with moderate to severe UC who completed a 52-week, phase 3 maintenance study(OCTAVE Sustain) were eligible to enroll into the ongoing, phase 3, multicenter, open-label,long-term extension (OCTAVE Open). We analyzed data from 142 patients who were inremission following tofacitinib treatment in OCTAVE Sustain who received tofacitinib 5 mgtwice daily during OCTAVE Open. We assessed efficacy (including remission [based on totalMayo score], endoscopic improvement, clinical response, and partial Mayo score up to month36 of OCTAVE Open) and safety data.
104
105
RESULTS:106
107
108
After 12 months of tofacitinib 5 mg twice daily in OCTAVE Open, 68.3% of patients were inremission, 73.9% had endoscopic improvement, and 77.5% had a clinical response. At month36, 50.4%, of the patients were in remission, 55.3% had endoscopic improvement, and 56.0%had a clinical response. The safety profile of tofacitinib 5 mg twice daily revealed no new safetyrisks associated with long-term exposure up to 36 months.
r: AE, adverse event; BID, twice daily; CI,alysis set; HZ, herpes zoster; IR, incidencerried forward; MACE, major adverse car-melanoma skin cancer; NRI, nonresponderlong-term extension; PMS, partial Mayotor inhibitor; UC, ulcerative colitis.
© 2020 by the AGA Institute1542-3565/$36.00
https://doi.org/10.1016/j.cgh.2020.10.004
LA 5.6.0 DTD � YJCGH57542_proof � 17 December 2020 � 7:19 pm � ce OB
109
110
111
112
113
114
115
116
Q5
2 Colombel et al Clinical Gastroenterology and Hepatology Vol. -, No. -
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
CONCLUSIONS:F
176
177
178
Efficacy endpoints were maintained for up to 36 months, regardless of prior tofacitinib dose,including patients who reduced from tofacitinib 10 mg to 5 mg twice daily upon OCTAVE Openentry. No new safety risks were identified. ClinicalTrials.gov: OCTAVE Sustain (NCT01458574);OCTAVE Open (NCT01470612).
179
180
Keywords: (3–4); JAK inhibitor; inflammatory bowel disease; response to therapy; active disease. 181182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
Patients with ulcerative colitis (UC) often requirelifelong medical therapy to control symptoms and
to avoid disease deterioration, hospitalization, andcolectomy.1 Remission, defined in both symptomatic andendoscopic terms, represents a preferred goal of UCmedical management strategies,2 with the ultimate goalbeing to achieve a sustained and durable period ofsteroid-free remission.3
Tofacitinib is an oral, small molecule Janus kinaseinhibitor for the treatment of UC. The efficacy and safetyof tofacitinib have been demonstrated in two 8-week,phase 3 induction studies (OCTAVE Induction 1 study[NCT01465763] and OCTAVE Induction 2 study[NCT01458951]) and a 52-week, phase 3 maintenancestudy (the OCTAVE Sustain study [NCT01458574]) inpatients with moderate to severe UC.4 Patients whocompleted the OCTAVE Sustain study, or had earlytreatment withdrawal due to treatment failure, wereeligible to enroll into the open-label, long-term extension(OLE) study (OCTAVE Open study [NCT01470612]).Study treatment was assigned depending on the patients’remission status at baseline of the OCTAVE Open study,with patients in remission assigned to receive tofacitinib5 mg twice daily (BID), and patients who did not meetthe remission definition assigned to receive tofacitinib 10mg BID. The efficacy and safety of tofacitinib treatmentin 2 patient subpopulations from the OCTAVE Openstudy that enrolled patients from the OCTAVE Induction1 or 2 studies or the OCTAVE Sustain study have previ-ously been reported.5 These analyses, reported by Sandset al,5 included 2 subgroups of patients: (1) tofacitinibinduction responders in remission following 52 weeks oftofacitinib 10 mg BID maintenance treatment and sub-sequently reduced to tofacitinib 5 mg BID (the dose de-escalation group) and (2) tofacitinib induction re-sponders who experienced treatment failure whilereceiving tofacitinib 5 mg BID maintenance treatmentand subsequently increased to tofacitinib 10 mg BID (thedose escalation group). The primary aim of the currentanalysis was to investigate the maintenance of efficacy byexamining a cohort of patients in remission after 52weeks of tofacitinib treatment in the OCTAVE Sustainstudy, who subsequently received open-label, long-termtreatment with tofacitinib 5 mg BID in the OCTAVE Openstudy. Maintenance of efficacy was assessed through themeasurement of remission, endoscopic improvement,clinical response, and partial Mayo score (PMS). Patients’steroid status was assessed throughout the OCTAVEOpen study. The secondary aim was to report safety datafor all patients who received tofacitinib 5 mg BID in the
LA 5.6.0 DTD � YJCGH57542_proof � 1
OCTAVE Open study (including those who entered theOCTAVE Sustain study in remission following treatmentwith placebo in the OCTAVE Sustain study).
Materials and Methods
Study Design
The OCTAVE Open study is an ongoing, phase 3,multicenter, OLE study that enrolled patients whocompleted or demonstrated treatment failure in theOCTAVE Sustain study, as well as patients whocompleted the OCTAVE Induction 1 and 2 studieswithout clinical response (Supplementary Figure 1).4
Here, we report efficacy and safety data (up to May2019) for patients who had completed the OCTAVESustain study and met the criteria for remission (definedas a total Mayo score �2, no individual subscore >1, anda rectal bleeding subscore of 0) at week 52 and receivedopen-label treatment with tofacitinib 5 mg BID duringthe OCTAVE Open study, independent of which treat-ment arm of the OCTAVE Sustain study they enteredfrom (Figure 1). Remission status at week 52 of theOCTAVE Sustain study was based on centrally read Mayoendoscopic subscore. For further study design details,see the Supplementary Methods.
Ethical Considerations
All studies were conducted in compliance with theDeclaration of Helsinki and the International Conferenceon Harmonisation Good Clinical Practice Guidelines, andwere approved by the institutional review boards orindependent ethics committees at each of the investiga-tional centers participating in the studies, or a centralinstitutional review board. All patients provided writteninformed consent.
Patient Disposition
Inclusion and exclusion criteria for the OCTAVE In-duction 1 and 2 and OCTAVE Sustain studies have beendescribed previously.4 Briefly, eligible patients were �18years of age, with a confirmed diagnosis of moderate tosevere UC (total Mayo score of 6–12, with a rectalbleeding subscore of 1–3 and an endoscopic subscore of2–3) for �4 months and had failed treatment with, orwere intolerant to, at least 1 of the following: oral orintravenous corticosteroids, azathioprine or 6-
7 December 2020 � 7:19 pm � ce OB
What You Need to Know
BackgroundWe evaluated the effects of long-term treatment withtofacitinib—an oral, small molecule Janus kinaseinhibitor in patient with ulcerative colitis.
FindingsMost patients who achieved remission after main-tenance treatment with either tofacitinib 5 mg or 10mg twice daily for 52 weeks maintained remissionover 36 months with tofacitinib 5 mg twice daily inan open-label, long-term extension study.
Implications for patient careFindings of the durability of efficacy with tofacitinib5 mg twice daily supports its use in long-termmaintenance therapy for patients with ulcerativecolitis in remission after 52 weeks of maintenancetherapy.
- 2020 Tofacitinib Maintenance of Remission in UC 3
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
mercaptopurine, or tumor necrosis factor inhibitors(TNFis) (infliximab or adalimumab).
Efficacy Assessments
Efficacy assessments utilized the Mayo score. In theOCTAVE clinical program, any friability on the endoscopysubscore meant a scoring of �2. For definitions ofremission, endoscopic improvement, and clinicalresponse, see the Supplementary Methods.
Remission, endoscopic improvement, and clinicalresponse were assessed at months 2 (centrally readendoscopy), 12, 24, and 36 (based on locally readendoscopic subscores) from baseline of the OCTAVEOpen study (endoscopic readings in the OCTAVE Sustainstudy were centrally read).
PMS remission was defined as a PMS �2 with noindividual subscore >1. PMS remission was assessed atvarious time points up to month 36 from baseline of theOCTAVE Open study.
Safety Assessments
During the course of treatment with tofacitinib 5 mgBID, safety outcomes were assessed, and the incidenceand severity of adverse events (AEs), classified in theMedical Dictionary for Regulatory Activities, includingAEs of special interest, were reported. See theSupplementary Methods for further details of AEs ofspecial interest. Patients underwent a 4-week safetyfollow-up evaluation after the last dose of studymedication.
Statistical Analysis
All data were analyzed descriptively. The full analysisset (FAS) was defined as all patients who received atleast 1 dose of study drug in the OCTAVE Open study.
Figure 1. Prior OCTAVE Induction and OCTAVE Sustain study tOpen study. For patients confirmed to be experiencing a flareincreased from 5 to 10 mg BID for the remaining treatment periopoints from baseline of the OCTAVE Sustain study, accompanieof �1 point, after a minimum of 8 weeks of treatment. Full schSupplementary Figure 1. aOne patient who was in remission at wmg BID) received tofacitinib 10 mg BID in the OCTAVE Open s
FLA 5.6.0 DTD � YJCGH57542_proof � 1
Efficacy outcomes were analyzed in the maintenanceremission subpopulation (patients who had receivedtofacitinib 5 or 10 mg BID during the OCTAVE Sustainstudy) of the FAS. Nonresponder imputation (NRI) wasapplied after a patient discontinued the study or after thedose escalation, and last observation carried forward(LOCF) imputation was applied after a patient advancedto a subsequent study up to the visit they would havereached if they had remained in the study. No imputationfor missing data was applied for ongoing patients, exceptNRI for intermittent missing data (NRI-LOCF). Observedcase data are also presented. Data after the dose esca-lation were excluded for the observed case.
Safety was assessed in all patients who received atleast 1 dose of tofacitinib 5 mg BID in the OCTAVE Openstudy, with no imputation for missing data.
reatments of patients in remission at baseline of the OCTAVEin the OCTAVE Open study, the tofacitinib dose could be
d. A flare was defined as an increase in total Mayo score of �3d by an increase in rectal bleeding and endoscopic subscoresematic details of the OCTAVE clinical program are shown ineek 52 of the OCTAVE Sustain study (treated with tofacitinib 5tudy.
7 December 2020 � 7:19 pm � ce OB
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
Q7
4 Colombel et al Clinical Gastroenterology and Hepatology Vol. -, No. -
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
All authors had access to the study data and reviewedand approved the final manuscript.
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
Results
Patient Characteristics
At week 52 of the OCTAVE Sustain study, based oncentral endoscopic reading, 163 patients were in remis-sion (maintenance remission subpopulation) and wereassigned to receive tofacitinib 5 mg BID during theOCTAVE Open study. Of the OCTAVE Open maintenanceremission subpopulation, 142 patients received tofaciti-nib 5 mg BID (n ¼ 66) or tofacitinib 10 mg BID (n ¼ 76)in the OCTAVE Sustain study (Figure 1). Twenty-onepatients within the maintenance remission subpopula-tion received placebo during the OCTAVE Sustain study;these patients were included in the baseline
Table 1. Patient Demographics and Baseline and ClinicalCharacteristics (FAS)
Maintenance RemissionSubpopulation (n ¼ 163)a
Female 75 (46.0)
Age, y 44.8 � 14.7
RaceWhite 125 (76.7)Asian 25 (15.3)Other 8 (4.9)Unspecified 5 (3.1)
BMI, kg/m2 25.7 � 4.8
Duration of diagnosis, y 7.7 � 6.6
RegionEurope 96 (58.9)North America 32 (19.6)Other 35 (21.5)
Treatment assignment inthe OCTAVE Sustain studyTofacitinib 5 mg BID 66 (40.5)Tofacitinib 10 mg BID 76 (46.6)Placebo BID 21 (12.9)
Corticosteroid-free atOCTAVE Open study baseline
162 (99.4)b
5-aminosalicylates useat OCTAVE Open study baseline
124 (76.1)
Total Mayo score 1.0 � 0.7
PMS 0.4 � 0.5
Values are n (%) or mean � SD.BID, twice daily; BMI, body mass index; FAS, full analysis set; OCTAVE, ���;PMS, partial Mayo score.aOne patient who was in remission at week 52 of the OCTAVE Sustain studyreceived tofacitinib 10 mg BID as a protocol deviation.bOne patient was receiving prednisone 7.5 mg daily at baseline of the OCTAVEOpen study.
FLA 5.6.0 DTD � YJCGH57542_proof � 1
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
demographics and clinical characteristics, and in thediscontinuations, but were not included within the effi-cacy analyses. Twelve patients who were not in remis-sion according to central endoscopic reading at entryinto the OCTAVE Open study also received tofacitinib 5mg BID but were not included in efficacy analyses pre-sented here.
Baseline demographics and disease characteristics forpatients in the maintenance remission subpopulation arepresented in Table 1. At baseline of the OCTAVE Openstudy, 162 of 163 patients were not receiving concomi-tant corticosteroids. See the Supplementary Results forfurther information relating to concomitantcorticosteroids.
Efficacy
The proportions of patients in the maintenanceremission subpopulation achieving remission, endo-scopic improvement, or clinical response during theOCTAVE Open study are shown in Figure 2. Observeddata show that rates of remission and endoscopicimprovement were generally maintained and broadlysimilar, irrespective of whether patients had receivedtofacitinib 5 or 10 mg BID during the OCTAVE Sustainstudy (Figure 2). PMS remission was maintained overtime in the majority of patients, and rates were similar,irrespective of whether patients had received tofacitinib5 or 10 mg BID during the OCTAVE Sustain study(Figure 3).
Ad hoc analysis of the maintenance of remissionpopulation showed that similar proportions of patientsmaintained remission or endoscopic improvementregardless of prior TNFi treatment status (Figure 2).
Within the maintenance remission subpopulation, 67(41.1%) patients discontinued treatment in the OCTAVEOpen study; see the Supplementary Results for furtherinformation relating to patient discontinuations.
Length of Time in Remission
Demographics and baseline characteristics weregenerally similar among patients in remission vs patientsnot in remission at month 12 of the OCTAVE Open study(Supplementary Table 1). Analysis of patients whoreduced tofacitinib dose from 10 to 5 mg BID in theOCTAVE Open study, by duration of remission, showsthat patients with a longer duration of remission in theOCTAVE Sustain study were more likely to stay inremission (Figure 4).
Dose Increase Due to Flare
Among the maintenance remission subpopulation,tofacitinib dose was increased from 5 to 10 mg BID dueto flare in 41 patients, of whom 37 had received tofaci-tinib (14 patients received tofacitinib 5 mg BID and 23
7 December 2020 � 7:19 pm � ce OB
Figure 2. ProportionQ6 ofpatients in the mainte-nance remission subpop-ulation who achievedremission or endoscopicimprovement, anddemonstrated clinicalresponse following treat-ment with tofacitinib 5 mgBID in the OCTAVE Openstudy by maintenancedose and prior TNFi treat-ment status (FAS; NRI-LOCF and observedcase). All values are perlocal read of endoscopy.Remission was defined asa total Mayo score �2 withno individual subscore >1,and a rectal bleeding sub-score of 0. Clinicalresponse was defined as adecrease from inductionstudy baseline total Mayoscore of �3 points and�30%, plus a decrease inrectal bleeding subscoreof �1 point or an absoluterectal bleeding subscoreof 0 or 1. NRI was appliedafter a patient dis-continued, and last obser-vation carried forwardimputation was appliedafter a patient advanced toa subsequent study up tothe visit they would havereached if they had stayedin the study. No imputationfor missing data wasapplied for ongoing pa-tients, except NRI forintermittent missing data.
- 2020 Tofacitinib Maintenance of Remission in UC 5
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
patients received tofacitinib 10 mg BID) during theOCTAVE Sustain study. Following dose escalation, 75.0%(n ¼ 30 of 40), 77.4% (n ¼ 24 of 31), 89.3% (n ¼ 25 of
FLA 5.6.0 DTD � YJCGH57542_proof � 1
28), and 95.0% (n ¼ 19 of 20) of patients achieved PMSremission at months 3, 6, 9, and 12, respectively(observed data). Corresponding NRI data were 73.2%
7 December 2020 � 7:19 pm � ce OB
Figure 3. Proportion ofpatients in the mainte-nance remission subpop-ulation who achieved PMSremission over timefollowing treatment withtofacitinib 5 mg BID in theOCTAVE Open study (FAS;NRI-LOCF and observedcase populations). PMSremission was defined as aPMS of �2 points, with noindividual subscore >1.
6 Colombel et al Clinical Gastroenterology and Hepatology Vol. -, No. -
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
(n ¼ 30 of 41), 58.5% (n ¼ 24 of 41), 64.1% (n ¼ 25 of39), and 48.7% (n ¼ 19 of 39), respectively(Supplementary Figure 2).
Safety
A total of 175 patients (163 patients in the mainte-nance of remission subpopulation [including the 142 pa-tients who received tofacitinib during the OCTAVE Sustainstudy and 12 placebo-treated patients, all of whom enteredthe OCTAVE Open study in remission] and 12 patientsreceiving tofacitinib 5 mg BID as protocol deviations) wereassigned to receive tofacitinib 5 mg BID in the OCTAVEOpen study, of whom 86.9% reported treatment-emergentAEs (Table 2). The most frequently reported treatment-emergent AEs by preferred term were “nasopharyngitis”(reported in 38 [21.7%] patients) and “worsening of UC”(reported in 41 [23.4%] patients). AEs in the tofacitinib 5mg BID subpopulation of OCTAVE Open showed no time-dependent increase when compared with safety datafrom OCTAVE Sustain study patients treated with
FLA 5.6.0 DTD � YJCGH57542_proof � 1
tofacitinib 5 or 10 mg BID (Table 2). The majority of in-fections were mild or moderate.
In patients receiving tofacitinib 5 mg BID during theOCTAVE Open study, herpes zoster (HZ) (nonserious andserious) occurred in 11 patients with an incidence rate(IR) (unique patients with events per 100 patient-yearsof exposure) of 2.1 (95% confidence interval [CI],1.1–3.8); 1 of these HZ events was reported as a seriousAE. A total of 6 (3.4%) patients had serious infections(IR, 1.1; 95% CI 0.4–2.5) ; 5 (2.9%) patients had malig-nancy (excluding nonmelanoma skin cancer [NMSC])events (IR, 1.0; 95% CI, 0.3–2.2), and 5 (2.9%) patientshad NMSC events (IR, 1.0; 95% CI, 0.3–2.3). One patienthad complicated appendicitis (adjudicated as a gastro-intestinal perforation). Of note, there were no events ofdeep vein thrombosis, pulmonary embolism, or death inpatients receiving tofacitinib 5 mg BID during theOCTAVE Open study. For further details on AEs, see theSupplementary Results.
In patients who required dose escalation due to flare,there was 1 case each of serious infection, HZ
7 December 2020 � 7:19 pm � ce OB
696
Figure 4. Proportion of patients who maintained remission at month 12 of the OCTAVE Open study, by duration of remission.Data are shown for patients who achieved remission at week 52 of the OCTAVE Sustain study with tofacitinib 10 mg BID andthen reduced to 5 mg BID in the OCTAVE Open study. Remission was defined as a total Mayo score �2 with no individualsubscore >1, and a rectal bleeding subscore of 0. Remission status in the OCTAVE Sustain study was based on central readof endoscopy: <6 months prior to dose reduction was defined as remission at week 52, but not week 24, regardless ofremission status at the OCTAVE Sustain study baseline; 6 to <12 months prior to dose reduction was defined as remission atboth weeks 24 and 52, but not at the OCTAVE Sustain study baseline; �12 months prior to dose reduction was defined asremission at the OCTAVE Sustain study baseline, week 24, and week 52.
- 2020 Tofacitinib Maintenance of Remission in UC 7
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
(nonserious; opportunistic infection), and malignancy(Supplementary Table 2).783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
Discussion
Tofacitinib is an oral, small molecule Janus kinaseinhibitor for the treatment of UC. This report presentspost hoc analysis of data from an OLE study of tofacitinibin a subpopulation of patients with moderate to severeUC meeting remission criteria following completion ofthe 52-week OCTAVE Sustain study,4 extending previousefficacy and safety findings by a further 36 months.Among patients who achieved remission during mainte-nance treatment, tofacitinib 5 mg BID demonstrateddurability of efficacy, with the majority of patientsmaintaining remission over 36 months in the OCTAVEOpen study, as evidenced across a range of endpointsincluding remission, endoscopic improvement, PMSremission, and clinical response. Rates of remission,endoscopic improvement, PMS remission, and clinicalresponse were sustained over 36 months of treatment,regardless of whether patients had previously receivedtofacitinib 5 or 10 mg BID during maintenance treatmentand regardless of their prior TNFi treatment status.
The maintenance of clinical response and clinicalremission are historically important goals in the man-agement of patients with UC. The OCTAVE study pro-tocols were approved prior to the publication of the U.S.Food and Drug Administration guidance for clinical trialendpoints6 and incorporated a more stringent definitionof remission (with the inclusion of a rectal bleeding
FLA 5.6.0 DTD � YJCGH57542_proof � 1
subscore of 0) than that used in other studies.4 Rates ofendoscopic improvement (defined as a Mayo endoscopicsubscore of 0 or 1) in the current analysis generally re-flected those of remission, suggesting the validity of thisendpoint in clinical practice. The use of PMS remission,which may represent a more practical outcome measure,given its avoidance of endoscopy, was associated withslightly higher remission rates over 12 months.
Data reported here, in which a high proportion ofpatients who demonstrated a response following 8weeks of tofacitinib treatment achieved and remained inremission following 3 years of treatment, are similar tothose reported in patients with other UC treatments.7–10
Of note, there are limited data from head-to-head studiescomparing long-term efficacy of approved agents,11 andprimary outcome measures were different acrossstudies, making direct comparisons difficult.
A high proportion of patients maintained remissionfollowing tofacitinib dose reduction from 10 mg BID inthe OCTAVE Sustain study to 5 mg BID in the OCTAVEOpen study. These open-label, uncontrolled data suggestthat once remission has been achieved on tofacitinib 10mg BID maintenance treatment, tofacitinib dose could bereduced while maintaining remission. The ad hoc anal-ysis presented here showed that length of time inremission may require consideration prior to dosereduction; however, these analyses are limited by thesmall patient numbers.
The majority of patients who entered the OCTAVEOpen study in remission and had their tofacitinib doseincreased from 5 to 10 mg BID due to flare achieved PMSremission by month 3 postdose increase; however, these
7 December 2020 � 7:19 pm � ce OB
Table 2. Summary of Safety Outcomes in the Tofacitinib 5 mg BID Treatment Group in the OCTAVE Open Study and, forComparison, the Tofacitinib 5 and 10 mg BID Treatment Groups in the OCTAVE Sustain Study
OCTAVE Open StudyaOCTAVE
Sustain Study
Tofacitinib5 mg BID (n ¼ 175)
Tofacitinib5 mg BID (n ¼ 198)
Tofacitinib10 mg BID (n ¼ 196)
Median duration of tofacitinib, d 1170 363.5 368
TEAEs 152 (86.9) 143 (72.2) 156 (79.6)
Deaths 0 (0.0), 0.0 (0.0–0.7) 0 (0.0), 0.0 (0.0–2.5) 0 (0.0), 0.0 (0.0–2.4)
SAEsb 33 (18.9) 10 (5.1) 11 (5.6)
Severe AEs 20 (11.4) 14 (7.1) 15 (7.7)
AEs leading to discontinuation 20 (11.4) 18 (9.1) 19 (9.7)
Infections 102 (58.3), 33.9 (27.6–41.1) 71 (35.9), 62.5 (48.9–78.9) 78 (39.8), 72.8 (57.6–90.9)
HZ (nonserious and serious)c 11 (6.3), 2.1 (1.1–3.8) 3 (1.5), 2.1 (0.4–6.0) 10 (5.1), 6.6 (3.2–12.2)
Serious infections 6 (3.4), 1.1 (0.4–2.5) 2 (1.0), 1.4 (0.2–4.9) 1 (0.5), 0.6 (0.0–3.5)
Opportunistic infectionsd,e 4 (2.3), 0.8 (0.2–2.0) 2 (1.0), 1.4 (0.2–4.9) 4 (2.0), 2.6 (0.7–6.7)
Serious HZ 1 (0.6), 0.2 (0.0–1.1) 0 (0.0), 0.0 (0.0–2.5) 0 (0.0), 0.0 (0.0–2.4)
Malignancies (excluding NMSC)d 5 (2.9), 1.0 (0.3–2.2) 0 (0.0), 0.0 (0.0–2.5) 0 (0.0), 0.0 (0.0–2.4)
NMSCd 5 (2.9), 1.0 (0.3–2.3) 0 (0.0), 0.0 (0.0–2.5) 3 (1.5), 1.9 (0.4–5.6)
Gastrointestinal perforationsd,f 1 (0.6), 0.2 (0.0–1.1) 0 (0.0), 0.0 (0.0–2.5) 0 (0.0), 0.0 (0.0–2.4)
MACEd 2 (1.1), 0.4 (0.1–1.4) 1 (0.5), 0.7 (0.0–3.8) 1 (0.5), 0.6 (0.0–3.5)
DVT 0 (0.0), 0.0 (0.0–0.7) 0 (0.0), 0.0 (0.0–2.5) 0 (0.0), 0.0 (0.0–2.4)
PE 0 (0.0), 0.0 (0.0–0.7) 0 (0.0), 0.0 (0.0–2.5) 0 (0.0), 0.0 (0.0–2.4)
Values are n (%) or incidence rate (95% confidence interval), unless otherwise indicated. Incidence rate is defined as unique patients with events per 100 patient-years of exposure; associated 95% confidence intervals were obtained by the exact Poisson method.AE, adverse event; BID, twice daily; DVT, deep vein thrombosis; HZ, herpes zoster; MACE, major adverse cardiovascular events; NMSC, nonmelanoma skincancer; PE, pulmonary embolism; SAE, serious adverse event; TEAE, treatment-emergent adverse event.aData are reported as per the May 27, 2019, data cut.bAccording to Investigator’s assessment.cRefer to the Supplementary Methods for preferred terms.dPer adjudication by specialist review committee.eExcludes tuberculosis and herpes zoster with 2 adjacent dermatomes.fExcludes preferred terms of pilonidal cyst, perirectal abscess, rectal abscess, anal abscess, perineal abscess, and any preferred terms using the term fistula.
8 Colombel et al Clinical Gastroenterology and Hepatology Vol. -, No. -
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
post hoc analyses are limited by the small sample size.Owing to the protocol design, endoscopy data in thesepatients who dose escalated were not available within a3-month window period.
The safety profile of tofacitinib 5 mg BID demonstratedno new safety risks associated with long-term exposure upto 36 months. Safety outcomes during the OCTAVE Openstudy were comparable to those of the OCTAVE Sustainstudy.4 Tofacitinib has been associated with an increasedrisk of HZ, but is not influenced by treatment duration.12,13
The majority of patients who had HZ were able to continuetofacitinib treatment or resume treatment following tem-porary discontinuation, consistent with the management ofHZ across other tofacitinib clinical programs.13 Safety inpatients who required dose escalation due to flare wasgenerally consistent with that observed in the OCTAVESustain study.4
FLA 5.6.0 DTD � YJCGH57542_proof � 1
Patients with inflammatory bowel disease receivingthiopurines have been reported to be at increased risk ofcertain types of malignancy, including lymphoma14 andNMSC.15 Observational data have shown the risk ofNMSC associated with thiopurines to continue followingdiscontinuation.15 In the maintenance of remission sub-population, 5 patients had malignancies (excludingNMSC), including 1 patient with diffuse large B celllymphoma. All patients with malignancies had priorexposure to thiopurines or TNFis; this was also true for 4of the 5 patients who had NMSC.
The remission status of patients completing theOCTAVE Sustain study was determined via central readendoscopy,4 whereas the OCTAVE Open study utilizedlocal endoscopy readings. Interpretation of endoscopicfindings by a local or central reader has the potential fordiscord between readings. During the OCTAVE Sustain
7 December 2020 � 7:19 pm � ce OB
928
- 2020 Tofacitinib Maintenance of Remission in UC 9
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
study, both locally and centrally read endoscopies wereperformed, both of which demonstrated the efficacy oftofacitinib as maintenance therapy vs placebo. Overall,local and central endoscopy readings were consistent,although efficacy by local endoscopy was numericallyhigher than when assessed by central endoscopy.16 TheOCTAVE Open study is an open-label study with noplacebo group; this has the potential to introduce bias inendoscopy outcomes. The analyses presented here onlyfocus on patients who were in remission at the end of theOCTAVE Sustain study and did not include those whomay have had a clinical response and were not inremission.
In conclusion, this post hoc analysis of data from theOCTAVE Open study demonstrated the durability of ef-ficacy with tofacitinib 5 mg BID and supports long-termmaintenance with tofacitinib 5 mg BID up to 36 monthsin patients who were in remission after 52 weeks ofmaintenance therapy. Efficacy rates were sustained over36 months of treatment, regardless of whether patientshad previously received tofacitinib 5 or 10 mg BID dur-ing maintenance treatment and regardless of their priorTNFi treatment status.
1010
1011
1012
1013
1014
1015
1016
1017
1018
Supplementary Material
Note: To access the supplementary material accom-panying this article, visit the online version of ClinicalGastroenterology and Hepatology at www.cghjournal.org,and at https://doi.org/10.1016/j.cgh.2020.10.004.
Q3Q41019
References 10201021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1. O’Connor A, Moss AC. Current and emerging maintenancetherapies for ulcerative colitis. Expert Rev Gastroenterol Hepatol2014;8:359–368.
2. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practiceguidelines for the medical management of nonhospitalized ul-cerative colitis: the Toronto consensus. Gastroenterology 2015;148:1035–1058.
3. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinicalguideline: ulcerative colitis in adults. Am J Gastroenterol 2019;114:384–413.
4. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as inductionand maintenance therapy for ulcerative colitis. N Engl J Med2017;376:1723–1736.
5. Sands BE, Armuzzi A, Marshall JK, et al. Efficacy and safety oftofacitinib dose de-escalation and dose escalation for patientswith ulcerative colitis: results from OCTAVE Open. AlimentPharmacol Ther 2020;51:271–280.
6. U.S. Food and Drug Administration. Ulcerative colitis: clinicaltrial endpoints guidance for industry. 2016. Available at: https://www.fda.gov/media/99526/download. Accessed April 8, 2020.
7. Loftus EV Jr, Colombel JF, Feagan BG, et al. Long-term efficacyof vedolizumab for ulcerative colitis. J Crohns Colitis 2017;11:400–411.
8. Noman M, Ferrante M, Bisschops R, et al. Vedolizumab induceslong-term mucosal healing in patients with Crohn’s disease andulcerative colitis. J Crohns Colitis 2017;11:1085–1089.
FLA 5.6.0 DTD � YJCGH57542_proof � 1
9. Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year mainte-nance treatment with adalimumab in patients with moderately toseverely active ulcerative colitis: data from ULTRA 1, 2, and 3.Am J Gastroenterol 2014;109:1771–1780.
10. Reinisch W, Colombel JF, Gibson PR, et al. Continuous clinicalresponse is associated with a change of disease course in pa-tients with moderate to severe ulcerative colitis treated withgolimumab. Inflamm Bowel Dis 2019;25:163–171.
11. Schreiber S, Peyrin-Biroulet L, Loftus EV Jr, et al. OP34 VAR-SITY: A double-blind, double-dummy, randomised, controlledtrial of vedolizumab versus adalimumab in patients with activeulcerative colitis [abstract]. J Crohns Colitis 2019;13:S612–S613.
12. Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zosterinfection in patients with ulcerative colitis receiving tofacitinib.Inflamm Bowel Dis 2018;24:2258–2265.
13. Colombel JF. Herpes zoster in patients receiving JAK inhibitorsfor ulcerative colitis: mechanism, epidemiology, management,and prevention. Inflamm Bowel Dis 2018;24:2172–2182.
14. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma inpatients with inflammatory bowel disease treated with azathio-prine and 6-mercaptopurine: a meta-analysis. Clin GastroenterolHepatol 2015;13:847–858.e4; quiz e48–e50.
15. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased riskfor nonmelanoma skin cancers in patients who receive thio-purines for inflammatory bowel disease. Gastroenterology 2011;141:1621–1628.
16. Feagan BG, Vermeire S, Sandborn WJ, et al. Tofacitinib formaintenance therapy in patients with active ulcerative colitis inthe phase 3 OCTAVE Sustain trial: results by local and centralendoscopic assessments [abstract]. Am J Gastroenterol 2017;112:S329–S330.
Reprint RequestsAddress requests for reprints to: Nervin Lawendy, PharmD, Pfizer Inc, 500Arcola Road, Collegeville, PA 19426. e-mail: nervin.lawendy@pfizer.com; fax:���.
AcknowledgmentsThe authors would like to thank the patients, investigators, and study teamsinvolved in the OCTAVE clinical program. Upon request, and subject to certaincriteria, conditions, and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provideaccess to individual de-identified participant data from Pfizer-sponsored globalinterventional clinical studies conducted for medicines, vaccines, and medicaldevices (1) for indications that have been approved in the United States and/orEuropean Union or (2) in programs that have been terminated (ie, developmentfor all indications has been discontinued). Pfizer will also consider requests forthe protocol, data dictionary, and statistical analysis plan. Data may berequested from Pfizer trials 24 months after study completion. The de-identifiedparticipant data will be made available to researchers whose proposals meetthe research criteria and other conditions, and for which an exception does notapply, via a secure portal. To gain access, data requestors must enter into adata access agreement with Pfizer.
Conflicts of InterestThese authors disclose the following: Jean-Frederic Colombel has acted as aconsultant for AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim,Celgene, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech,Gilead, Janssen, MedImmune, Merck & Co, Nextbiotix, Novartis, OtsukaPharmaceutical Development and Commercialization, Pfizer, Protagonist,Second Genome, Seres Therapeutics, Shire, Takeda, and Theradiag; hasreceived financial support for research from AbbVie, Intestinal Biotech Devel-opment, and Janssen and Janssen; and has participated in speakers’ bureausfor AbbVie, Celgene, Ferring Pharmaceuticals, Genfit, and Takeda. Mark T.Osterman has acted as an advisory board member for AbbVie, Elan, Janssen,Lycera, Merck & Co, Pfizer, Takeda, and UCB. Andrew J. Thorpe, LeonardoSalese, Chudy I. Nduaka, Haiying Zhang, Nervin Lawendy, Gary S. Friedman,Daniel Quirk, and Chinyu Su are employees and stockholders of Pfizer. WalterReinisch has acted as a consultant for 4SC, Abbott Laboratories, AbbVie,Aesca, Amgen, AM Pharma, AOP Orphan, Arena Pharmaceuticals, Astellas,AstraZeneca, Avaxia, Bioclinica, Biogen IDEC, Boehringer Ingelheim,
7 December 2020 � 7:19 pm � ce OB
Q10
10 Colombel et al Clinical Gastroenterology and Hepatology Vol. -, No. -
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
Bristol-Myers Squibb, Celgene, Cellerix, Celltrion, Centocor, ChemoCentryx,Covance, Danone Austria, Elan, Eli Lilly, Ernst & Young, Falk Pharma GMbH,Ferring Pharmaceuticals, Galapagos, Genentech, Gilead, Grünenthal, ICON,Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko KirinPharma, Lipid Therapeutics, LivaNova, Mallinckrodt, MedAhead, MedImmune,Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestlé, Novartis,Ocera, Otsuka, Parexel, PDL, Pfizer, Pharmacosmos, Philip Morris Institute,Proctor & Gamble, Prometheus Laboratories, Protagonist, Provention, RobartsClinical Trials, Roland Berger GmBH, Sandoz, Schering-Plough, SecondGenome, Seres Therapeutics, SetPoint Medical, Sigmoid, Takeda, Therakos,TiGenix, UCB, Vifor, Zealand, and Zyngenia; he has participated in speakers’bureaus for Abbott Laboratories, AbbVie, Aesca, Aptalis, Astellas, Celltrion,Centocor, Danone Austria, Elan, Falk Pharma GMbH, Ferring Pharmaceuticals,Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL,Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos,Vifor, and Yakult; he has received financial support for research from Abbott
FLA 5.6.0 DTD � YJCGH57542_proof � 1
Laboratories, AbbVie, Aesca, Centocor, Falk Pharma GMbH, Immundiagnostik,and MSD; and he has acted as an advisory board member for 4SC, AbbottLaboratories, AbbVie, Aesca, Amgen, AM Pharma, Astellas, AstraZeneca,Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene,Cellerix, Celltrion, Centocor, ChemoCentryx, Danone Austria, Elan, FerringPharmaceuticals, Galapagos, Genentech, Grünenthal, Inova, Janssen, John-son & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune,Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestlé, Novartis,Ocera, Otsuka, PDL, Pfizer, Pharmacosmos, Proctor & Gamble, PrometheusLaboratories, Sandoz, Schering-Plough, Second Genome, SetPoint Medical,Takeda, Therakos, TiGenix, UCB, Zealand, and Zyngenia.
FundingThis study was sponsored by and funding for medical writing support wasprovided by Pfizer.
7 December 2020 � 7:19 pm � ce OB
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
Q9
- 2020 Tofacitinib Maintenance of Remission in UC 10.e1
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
Supplementary Methods
Dose Increase Due to Flare
At or after month 2 of the OCTAVE Open study,patients experiencing a flare could dose escalate tofa-citinib from 5 to 10 mg twice daily (BID). A flare wasdefined as an increase in total Mayo score of �3 pointsfrom baseline of the OCTAVE Sustain study, accompa-nied by an increase in rectal bleeding and site-readendoscopic subscore of �1 point, after a minimum of8 weeks of treatment in the OCTAVE Open study. Pa-tients who increased tofacitinib dose from 5 to 10 mgBID due to flare were excluded from the observed dataefficacy analysis, but treated as nonresponder imputa-tion (NRI) after dose escalation for NRI and lastobservation carried forward (NRI-LOCF) imputationdata.
Concomitant Medication
Patients were permitted to use concomitant oral 5-aminosalicylates or sulfasalazine.
Prohibited medications included azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, mycophe-nolate, tacrolimus, interferon, tumor necrosis factor in-hibitors, intravenous or rectally administeredcorticosteroids, and natalizumab, vedolizumab, or otherantiadhesion molecule therapy. Patients were permittedto use concomitant oral corticosteroids up to 25 mg/d during induction but had to undergo mandatorytapering during maintenance. If the patients entered theOCTAVE Open study on oral corticosteroids, taperingwas mandatory.1
If the patient was unable to tolerate tapering below10 mg/d, corticosteroids were permitted if the dosedid not exceed 10 mg/d. Once corticosteroid-freestatus was achieved, reinitiation of oral corticoste-roid therapy above 10 mg/d was considered rescuetherapy, and patients were required to discontinuefrom the study.
Study Discontinuation
Patients within the maintenance of remission cohortwere required to withdraw from the study if they initi-ated a new therapy for ulcerative colitis (UC), underwentsurgery for UC, or remained on corticosteroids exceeding15 mg/d of prednisone or equivalent after month 3, or ifthere were any safety concerns.
Mayo Score
Efficacy assessments utilized the Mayo score, whichranges from 0 to 12 points and comprises 4 subscores(graded from 0 to 3): stool frequency, rectal bleeding,and mucosal appearance on endoscopy (centrally read),
FLA 5.6.0 DTD � YJCGH57542_proof � 1
and physician global assessment. The partial Mayo scoremeasures disease activity in UC without endoscopy, andranges from 0 to 9 points. It comprises 3 subscores(graded from 0 to 3): stool frequency, rectal bleeding,and physician global assessment.
Efficacy Endpoints
Remission was defined as a total Mayo score �2 withno individual subscore >1, and a rectal bleeding sub-score of 0. Endoscopic improvement was defined as aMayo endoscopic subscore of 0 or 1 (defined as mucosalhealing in the OCTAVE study protocols. In the OCTAVEclinical program, any friability on the endoscopy sub-score meant a scoring of �2. Clinical response wasdefined as a decrease from induction study baseline totalMayo score of �3 points and �30%, plus a decrease inrectal bleeding subscore of �1 point or an absolute rectalbleeding subscore of 0 or 1.
Adverse Events of Special Interest
Adverse events (AEs) of special interest includedserious infection events (any infection AE that requiredthe infection to be classified as a serious AE [SAE]),herpes zoster (HZ), malignancies (excluding non-melanoma skin cancer [NMSC]), NMSC, gastrointestinalperforations, and major adverse cardiovascular events.In order to harmonize and standardize endpointassessment, opportunistic infections, major adverse car-diovascular events, malignancy, and gastrointestinalperforation events were based on adjudication byspecialist review committees.
HZ AEs corresponded to the system organ class ofinfections and infestations; preferred terms included“Herpes zoster,” “Herpes zoster disseminated,” “Her-pes zoster cutaneous disseminated,” “OphthalmicHerpes zoster,” “Herpes zoster oticus,” “Genital Her-pes zoster,” “Herpes zoster pharyngitis,” “Herpeszoster necrotizing retinopathy,” “Herpes zoster infec-tion neurological,” “Herpes zoster meningitis,” “Her-pes zoster meningomyelitis,” and “Herpes zostermeningoencephalitis.”
Supplementary Results
Concomitant Corticosteroids
One patient who was receiving prednisone 7.5 mgdaily was enrolled into the OCTAVE Open study as aprotocol deviation. One patient who was not receivingcorticosteroids at baseline of the OCTAVE Open studyreceived prednisone (20 mg/d) for 2 days (days 36 and37) during the OCTAVE Open study. Neither of thesepatients met the criteria for patient withdrawal, and bothcontinued to participate in the study.
7 December 2020 � 7:19 pm � ce OB
10.e2 Colombel et al Clinical Gastroenterology and Hepatology Vol. -, No. -
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
Discontinuations
Within the maintenance remission subpopulation, 67(41.1%) patients discontinued treatment in the OCTAVEOpen study: 26 of 67 (38.8%) patients discontinued forstudy drug–related reasons, and 41 of 67 (61.2%) dis-continued for nonstudy drug–related reasons. Of thepatients who withdrew due to reasons related to thestudy drug, 15 (9.2%) discontinued due to insufficientclinical response, and 11 (6.7%) discontinued due to AEs(excluding worsening of UC). Of the 15 patients whodiscontinued due to insufficient clinical response, 3 hadreceived placebo during the OCTAVE Sustain study, 6had received tofacitinib 5 mg BID, and 6 had receivedtofacitinib 10 mg BID. One patient who discontinued inthe OCTAVE Open study was enrolled directly from theOCTAVE Induction study and assigned to tofacitinib 5 mgBID as a protocol deviation. Nonstudy drug–relatedreasons for study discontinuation included AEs (n ¼ 5of 41, 12.2%), patient no longer willing to participate(n ¼ 16 of 41, 39.0%), protocol violation (n ¼ 2 of 41,4.9%), lost to follow-up (n ¼ 2 of 41, 4.9%), pregnancy(n ¼ 2 of 41, 4.9%), and other reasons (n ¼ 14 of 41,34.1%) (including enrollment into postmarketingsurveillance).
Safety
A total of 6 (3.4%) patients had serious infections;however, there was no specific clustering, with 1 eventeach of appendicitis, gastroenteritis norovirus, HZ,necrotizing fasciitis, pulmonary mycosis, and tonsillitis.
FLA 5.6.0 DTD � YJCGH57542_proof � 1
Five patients who received tofacitinib 5 mg BIDduring the OCTAVE Open study had malignancy(excluding NMSC) events, including 1 event each of lungcancer, cervical dysplasia, and diffuse large B cell lym-phoma, and 2 patients had breast cancer. All patientsdiscontinued in the study, with the exception of the pa-tient with cervical dysplasia. Three patients with malig-nancy events had prior immunosuppressant therapy use,and 2 had prior tumor necrosis factor inhibitor use.
Of the 11 patients with HZ, 3 patients had receivedtofacitinib 10 mg BID during the OCTAVE Sustain study,4 patients had received tofacitinib 5 mg BID, and 4 pa-tients had received placebo. Two patients discontinuedthe study due to HZ events, and 2 required temporarydiscontinuation of treatment; all other patientscontinued in the study and treatment was not inter-rupted. Five patients who received tofacitinib 5 mg BIDduring the OCTAVE Open study had NMSC events; 4patients had prior immunosuppressant use, and 2 hadprior tumor necrosis factor inhibitor use.
Three patients, all of whom had a history of NMSC,had multiple NMSC events during the OCTAVE Openstudy. One patient developed appendicitis on day 10 ofthe OCTAVE Open study, underwent an appendectomy,and was adjudicated as a gastrointestinal perforation.
Tofacitinib was discontinued following this event,which was deemed unrelated to the study drug.
7 De
References
1. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as inductionand maintenance therapy for ulcerative colitis. N Engl J Med2017;376:1723–1736.
cember 2020 � 7:19 pm � ce OB
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
Supplementary Figure 2. Proportion of patients in the maintenance remission–dose escalation subpopulation with partialMayo score (PMS) remission. PMS remission was defined as a PMS �2 with no individual subscore >1. Error bars are exactbinomial 90% confidence intervals (Clopper-Pearson method). Nonresponder imputation (NRI) was applied after a patientdiscontinued the study, and last observation carried forward (LOCF) imputation was applied after a patient advanced to asubsequent study up to the visit they would have reached if they had remained in the study. No imputation for missing datawas applied for ongoing patients, except NRI for intermittent missing data (NRI-LOCF).
web4C=FPO
Supplementary Figure 1. Study design (overview of the phase 3 OCTAVE Q8program). aFinal complete efficacy assessment atweek 8 of 52. Treatment continued up to week 9 of 53. bClinical response in the OCTAVE Induction 1 and 2 studies wasdefined as a decrease from baseline total Mayo score of �3 points and �30%, plus a decrease in rectal bleeding subscore of�1 point or an absolute rectal bleeding subscore of 0 or 1. cStudy A3921139 (OCTAVE Open study) is ongoing. dRemissionwas defined as a total Mayo score �2 with no individual subscore >1, and a rectal bleeding subscore of 0. In the OCTAVEOpen study, 12 patients not in remission at OCTAVE Open study entry received tofacitinib 5 mg twice daily (BID) and 1 patientin remission at OCTAVE Open study entry received tofacitinib 10 mg BID as protocol deviations.
FLA 5.6.0 DTD � YJCGH57542_proof � 17 December 2020 � 7:19 pm � ce OB
- 2020 Tofacitinib Maintenance of Remission in UC 10.e3
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
Supplementary Table 1. Patient Characteristics by OCTAVE Open Study Month 12 Remission Status Among Patients WhoAchieved Remission During OCTAVE Sustain Study
OCTAVE Open Study Month 12 Remission Status (as Observed)a
OCTAVE Sustain Study: Tofacitinib 10 mg BID OCTAVE Sustain Study: Tofacitinib 5 mg BID
In Remission(n ¼ 56)
Not in Remission(n ¼ 12)
In Remission(n ¼ 49)
Not in Remission(n ¼ 8)
Male 25 (45) 5 (42) 28 (57) 6 (75)
Age at OCTAVE Inductionstudy baseline, y
46.0 � 14.8 42.4 � 16.2 44.5 � 14.4 38.1 � 16.7
Total Mayo score at OCTAVEInduction study baseline
8.7 � 1.6 8.0 � 1.3 8.5 � 1.5 8.8 � 1.9
Endoscopic subscore atOCTAVE Open study baseline
0 17 (30) 5 (42) 23 (47) 3 (38)
1 39 (70) 7 (58) 26 (53) 5 (63)
CRP at OCTAVEOpen study baseline
<3 mg/L 49/56 (88) 9/10 (90) 41/49 (84) 7/8 (88)
�3 mg/L 7/56 (13) 1/10 (10) 8/49 (16) 1/8 (13)
Extent of disease atOCTAVE Induction study baseline
Proctosigmoiditis 11/55 (20) 5/12 (42) 9/49 (18) 1/8 (13)
Left-sided colitis 16/55 (29) 5/12 (42) 14/49 (29) 4/8 (50)
Extensive colitis/pancolitis 28/55 (51) 2/12 (17) 26/49 (53) 3/8 (38)
Prior TNFi failure at OCTAVEInduction study baseline
25 (45) 6 (50) 14 (29) 2 (25)
Values are n (%), mean � SD, or n/n (%).Remission was defined as a total Mayo score �2 with no individual subscore >1, and a rectal bleeding subscore of 0. PMS remission was defined as a PMS of �2with no individual subscore >1.BID, twice daily; CRP, C-reactive protein; PMS, partial Mayo score; TNFi, tumor necrosis factor inhibitor.aRemission status in the OCTAVE Open study was based on local read of endoscopy.
FLA 5.6.0 DTD � YJCGH57542_proof � 17 December 2020 � 7:19 pm � ce OB
10.e4 Colombel et al Clinical Gastroenterology and Hepatology Vol. -, No. -
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
Supplementary Table 2. Summary of Safety Outcomes in the Maintenance Remission-Dose Escalation Subpopulation of theOCTAVE Open Study
Tofacitinib Maintenance Remission-DoseEscalation Subpopulation (n ¼ 41)a
AEs 40 (97.6)
SAEsb 6 (14.6)
AEs leading to discontinuation 4 (9.8)
Deathsc 0 (0.0), 0.0 (0.0–3.0)
Serious infections 1 (2.4), 0.8 (0.0–4.6)
HZ (nonserious and serious) 1 (2.4), 0.8 (0.0–4.6)
Opportunistic infectionsd 1 (2.4), 0.8 (0.0–4.6)
Non-HZ opportunistic infectionsd 0 (0.0), 0.0 (0.0–3.0)
Malignancies (excluding NMSC)c,d 1 (2.4), 0.8 (0.0–4.6)
NMSCc,d 3 (7.3), 2.6 (0.5–7.5)
MACEc,d 0 (0.0), 0.0 (0.0–3.0)
DVT 0 (0.0), 0.0 (0.0–3.0)
PE 0 (0.0), 0.0 (0.0–3.0)
Values are n (%) or incidence rate (95% confidence interval).Incidence rate is defined as unique patients with events per 100 patient-years of exposure; associated 95% confidence intervals were obtained by the exactPoisson method.AE, adverse event; DVT, deep vein thrombosis; HZ, herpes zoster; MACE, major adverse cardiovascular events; NMSC, nonmelanoma skin cancer; PE, pulmonaryembolism; SAE, serious adverse event.aData are reported as per the May 27, 2019, data cut.bAccording to Investigator’s assessment.cAll events, including those that are outside the 28-day risk period, are included.dPer adjudication by specialist review committee.
FLA 5.6.0 DTD � YJCGH57542_proof � 17 December 2020 � 7:19 pm � ce OB
- 2020 Tofacitinib Maintenance of Remission in UC 10.e5
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
PP-XEL-CAN-0718-EN